Alveolar Septal Fibroblast Loss and The Pathogenesis of Emphysema

肺泡间隔成纤维细胞丢失与肺气肿的发病机制

基本信息

项目摘要

Commonly diagnosed among male US Veterans of advancing age and with prior history of cigarette smoking, emphysema is a chronic lung disease in which loss of the alveolar-capillary gas exchange units ultimately leads to end-stage respiratory insufficiency. Thus, understanding the mechanisms underlying lung function impairment in emphysema and developing strategies to mitigate its development remains at the forefront of research into US Veteran’s health. Emphysema is associated with alveolar septal thinning, loss of extracellular matrix (ECM), especially elastin and collagen, and alveolar simplification due to loss of alveolar epithelial cells, endothelial cells and fibroblasts. While considerable attention has been focused on understanding how cigarette smoke (CS) exposure adversely impacts alveolar epithelial cells and endothelial cells, little is known about its effect on alveolar septal fibroblasts, which provide essential trophic and structural support to the alveolar epithelium. Using 2 validated mouse models of emphysema, we have observed that PDGFRα+ alveolar fibroblasts are eliminated from alveolar walls and septa prior to the pathologic development of airspace enlargement, raising the question of whether this event may play a causal and previously unexplored role in emphysema. Therefore, the goal of this VA Merit Award application is to test the hypothesis that emphysema is initiated by programmed cell death and loss of alveolar fibroblasts, which in turn leads to loss of trophic support to the alveolar epithelium. Through the use of genetic cell ablation and gain- and loss-of-function approaches in mice, we propose testing this hypothesis with three Specific Aims. Aim 1 will test the hypothesis that alveolar wall and septal fibroblast programmed cell death precedes the development of emphysema and leads to disrupted crosstalk with, and support to, alveolar epithelial cells. This hypothesis will be tested by investigating which alveolar fibroblast subsets are lost during emphysema development, when they are lost, the type of programmed cell death that occurs, and how their loss functionally affects alveolar epithelial cells. Aim 2 will test the hypothesis that loss of alveolar fibroblasts is sufficient to initiate the development of emphysema. This hypothesis will be tested using a conditional fibroblast ablation strategy followed by assessment of the rate of alveolar epithelial cell loss and emphysema development. The role of loss of specific alveolar fibroblast subsets in emphysema development will subsequently be determined by conditionally ablating defined lung fibroblast subsets. Lastly, Aim 3 will test the hypothesis that preventing alveolar fibroblast programmed cell death will maintain alveolar structural support and prevent emphysema development. This hypothesis will be tested in two phases. First, we will investigate the mechanisms of programmed cell death, with a focus on apoptosis and necroptosis. Second, based on this information, we will conditionally express the anti-apoptotic gene, Bcl-2, or functionally inactivate the necroptosis pathway by conditional RIPK3 or MLKL inactivation, in defined alveolar fibroblast subsets and determine the ability of the mice to respond to cigarette smoke induced airspace enlargement. Although alveolar septal fibroblasts have long been known to be positioned adjacent to, and in intimate contact with the alveolar epithelium, remarkably little is known about how early fibroblast programmed cell death and functional loss may be necessary and/or sufficient to promote the development of emphysema. The proposed studies will address this key knowledge gap. Additionally, identifying methods to prevent alveolar fibroblast loss could lead to new opportunities to target this process as a strategy to prevent emphysema development.
该病常见于老年男性美国退伍军人和既往吸烟史,

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David W. Riches其他文献

David W. Riches的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David W. Riches', 18)}}的其他基金

Targeting early events in MUC5B-driven lung injury and fibrosis
针对 MUC5B 驱动的肺损伤和纤维化的早期事件
  • 批准号:
    10627600
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Alveolar Septal Fibroblast Loss and The Pathogenesis of Emphysema
肺泡间隔成纤维细胞丢失与肺气肿的发病机制
  • 批准号:
    10367957
  • 财政年份:
    2017
  • 资助金额:
    --
  • 项目类别:
Therapeutic Targeting of PTPN13 in Idiopathic Pulmonary Fibrosis
PTPN13 在特发性肺纤维化中的治疗靶向
  • 批准号:
    9142965
  • 财政年份:
    2017
  • 资助金额:
    --
  • 项目类别:
Aspen Lung Conference: Rebuilding the Injured Lung
阿斯彭肺会议:重建受伤的肺
  • 批准号:
    8711900
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
DUSP1 as a therapeutic target in fibroproliferative acute lung injury
DUSP1作为纤维增殖性急性肺损伤的治疗靶点
  • 批准号:
    8503966
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
Initial functional characterization of TRUSS-deficient mice
TRUSS 缺陷小鼠的初步功能表征
  • 批准号:
    8511974
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
Initial functional characterization of TRUSS-deficient mice
TRUSS 缺陷小鼠的初步功能表征
  • 批准号:
    8649023
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
DUSP1 as a therapeutic target in fibroproliferative acute lung injury
DUSP1作为纤维增殖性急性肺损伤的治疗靶点
  • 批准号:
    8665478
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
DUSP1 as a therapeutic target in fibroproliferative acute lung injury
DUSP1作为纤维增殖性急性肺损伤的治疗靶点
  • 批准号:
    9066180
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
Lung specific TNF-R1 signaling in TRUSS null mice
TRUSS 无效小鼠的肺特异性 TNF-R1 信号传导
  • 批准号:
    7496933
  • 财政年份:
    2007
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了